Abstract
This article will focus on basic concepts in the development of new agents for pediatric malignancies and future directions, while considering the limitations we have today and the lessons we have learned from adult cancers. In addition, basic ethical principles for conducting trials in children are summarized. The rising numbers of targeted agents that have become available over the last few years will significantly change the way clinical studies are planned and a shift towards the use of alternative end points, different selection criteria and innovative designs is necessary. Pediatric malignancies have specific particularities and disparities that distinguish them regarding the conduction and design of clinical trials, which may influence the use of novel compounds. Due to the rarity of these diseases, international groups have cooperated to increase accrual rates, and incentives to the pharmaceutical companies have been made available by regulatory authorities; however, despite this a lack of trial p...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
